Stockscreener 앱 받기
40.27
7.27%
2.73
시간 외 거래:
40.10
-0.17
-0.42%
전일 마감가:
$37.54
열려 있는:
$37.54
하루 거래량:
953.20K
Relative Volume:
1.71
시가총액:
$2.34B
수익:
-
순이익/손실:
$-146.66M
주가수익비율:
-14.62
EPS:
-2.7541
순현금흐름:
$-133.21M
1주 성능:
+32.60%
1개월 성능:
+16.76%
6개월 성능:
-20.45%
1년 성능:
-39.19%
1일 변동 폭
$35.94
$41.26
1주일 범위
$29.26
$41.26
52주 변동 폭
$29.26
$72.29
Apogee Therapeutics Inc Stock (APGE) Company Profile
명칭
Apogee Therapeutics Inc
전화
650-394-5230
주소
221 CRESCENT ST., WALTHAM
APGE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
40.27 | 2.34B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-25 | 개시 | Canaccord Genuity | Buy |
| 2024-05-10 | 개시 | BofA Securities | Buy |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | Guggenheim | Buy |
| 2023-08-08 | 개시 | Jefferies | Buy |
| 2023-08-08 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
| 2023-08-08 | 개시 | Wedbush | Outperform |
모두보기
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
Apogee Therapeutics signs manufacturing deal with Samsung Biologics - Investing.com
Apogee Therapeutics IncEnters Master Services Agreement With Samsung Biologics - Marketscreener.com
TD Cowen reiterates buy on Apogee Therapeutics stock - Investing.com India
Strong Buy Recommendation for Apogee Therapeutics Driven by Promising Clinical Data and Strategic Pipeline Developments - TipRanks
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial - AOL
Apogee Therapeutics CEO Michael Henderson sells $301,511 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics CMO Carl Dambkowski sells $48,463 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics CMO Carl Dambkowski sells $48,463 in stock - Investing.com
Q1 EPS Estimates for Apogee Therapeutics Reduced by Wedbush - Defense World
Apogee Therapeutics (NASDAQ:APGE) Given Outperform Rating at Wedbush - MarketBeat
New York State Common Retirement Fund Increases Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year Low After Earnings Miss - Defense World
Apogee Therapeutics: Buy Rating Backed by Promising Data and Strong Financial Position - TipRanks
Where are the Opportunities in (APGE) - Stock Traders Daily
Optimistic Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trial Developments - TipRanks
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Handelsbanken Fonder AB - Defense World
Apogee Therapeutics (NASDAQ:APGE) Receives “Outperform” Rating from Wedbush - Defense World
Apogee Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results - GlobeNewswire
Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy - Investing.com India
Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy By Investing.com - Investing.com South Africa
Apogee Therapeutics price target raised to $116 from $110 at Guggenheim - TipRanks
Apogee Therapeutics Reports Positive Phase 1 Results - TipRanks
Apogee Therapeutics, Inc. Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG990 - Marketscreener.com
Apogee Therapeutics Full-Year Loss Widens -March 03, 2025 at 06:56 am EST - Marketscreener.com
Apogee Therapeutics, Inc. SEC 10-K Report - TradingView
Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial - Marketscreener.com
Apogee Therapeutics Advances Clinical Pipeline for APG777 and APG279, Reports Strong Cash Position and 2024 Financial Results - Nasdaq
Can Apogee's Overenrolled Clinical Trial Fast-Track Its Challenge to DUPIXENT? - StockTitan
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy - The Bakersfield Californian
Apogee Therapeutics Announces Positive Interim Phase 1 - GlobeNewswire
Could Apogee's New Antibody End Monthly Injections for Chronic Inflammation Patients? - StockTitan
Rhumbline Advisers Has $2.39 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives $89.71 Average PT from Analysts - Defense World
Apogee Therapeutics (APGE) to Release Earnings on Tuesday - Defense World
Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now? - Insider Monkey
Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives $89.71 Average Target Price from Brokerages - MarketBeat
Apogee Therapeutics to Host Conference Call to Report - GlobeNewswire
Can Apogee's APG990 Clinical Data Transform Its Inflammatory Disease Pipeline? - StockTitan
Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week LowHere's Why - MarketBeat
1 Biotech Stock to Buy in 2025, and 1 to Avoid - AOL
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%. - AOL
Apogee Therapeutics (APGE) Projected to Post Earnings on Tuesday - MarketBeat
Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs - AOL
Apogee Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewswire
How Will Apogee Therapeutics Address Investors at March Healthcare Conferences? - StockTitan
(APGE) Trading Report - Stock Traders Daily
Interesting APGE Put And Call Options For October 17th - Nasdaq
Apogee Therapeutics (NASDAQ:APGE) Reaches New 12-Month LowHere's What Happened - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Shares Down 7.1%Here's Why - MarketBeat
Apogee Therapeutics' (APGE) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Apogee Therapeutics Inc (APGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.14%
2.83%
자본화:
|
볼륨(24시간):